ClinicalTrials.gg
CompletedNCT07409675Updated Feb 13, 2026

Development of a Clinical Photographic Atlas for Skin Aging Based on the Characterization of Facial Dermal Collagen Using LC-OCT Technology

An observational study in Healthy Subjects and Healthy Adult, sponsored by Vichy Laboratoires. Completed at 1 site in France. Open to female participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Vichy Laboratoires · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
250
Ages
20 Years to 75 Years
Sex
Female
01

Study summary

This is a single-center, single visit study conducted in healthy female subjects, aged 20 to 75 years inclusive meeting specific inclusion/exclusion criteria. The study is to develop a clinical photographic atlas to assess skin aging by studying the relationship between age, sun exposure and quantity of collagen measured non-invasively (LC-OCT). No product will be tested during the study.

Read the detailed description

Single-center, single visit study in healthy female subjects, aged 20 to 75 years inclusive meeting specific inclusion/exclusion criteria. The study is to develop a clinical photographic atlas to assess skin aging by studying the relationship between age, sun exposure and quantity of collagen measured non-invasively (LC-OCT). No product will be tested during the study.

02

Conditions studied

  • Healthy Subjects
  • Healthy Adult

Keywords

  • skin aging
  • collagen
  • LC-OCT
03

In context

Lead sponsor

Vichy Laboratoires is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy female volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject having signed an Form (ICF) before any trial related activity is carried out;
  • Healthy female subject aged 20 to 75 years inclusive at the time of signing the ICF;
  • Subject with a phototype I to III on Fitzpatrick's scale;
  • Subject who is willing to follow the study procedures and to complete the study course;
  • Subject registered with Social Security in agreement with French law on study research.

Exclusion criteria

Exclusion Criteria:

  • Male subject;
  • Female subject who is pregnant or who is breast feeding;
  • Subject with current participation in any other interventional clinical study, based on interview of the subject;
  • Subject with facial dermatitis, rosacea, acne, eczema, psoriasis, skin rashes, open lesions, vitiligo or viral conditions such as herpes labialis;
  • Subject who has collagen vascular disease, a significant systemic disease, immunological problems or inflammatory skin conditions on the face;
  • Subject who has had a face lift;
  • Subject has had a non-ablative and/or ablative laser procedure on the face in the past 3 months;
  • Subject with a history of botulinum toxin or mesotherapy injections on the face within the last 6 months, or absorbable fillers injections (such as hyaluronic acid or autologous fat…) in the last 12 months or injectable implants (semi-permanent fillers) within the last 24 months;
  • Subject having done a moderate to deep peeling or non-invasive rejuvenation techniques such as radiofrequency, ultrasound and lasers in the last 6 months;
  • Subject having applied any cosmetic product (care cream, lotion, makeup) except usual cleansing products or any drug to her face on the day of the visit;
  • Subject who has been deprived of their freedom by administrative or legal decision, or who is under care of a guardian or legal guardianship, or subject hospitalized in a medical or social establishment for any reason.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
250 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Group 1: 20-30 years

    The subjects will attend one single visit during which standardized photographs of the face (front and 45° left and right sides), photo shooting with a smartphone (back and front captures), LC-OCT microscopy image acquisition will be realized. The subject will have also to answer a questionnaire.

    Diagnostic Test: LC-OCT acquisitions on the forehead · Device: Perform standardized photographs using ColorFace · Device: LC-OCT acquisitions on forehead · Device: Perform photo-shooting using smartphones

  • Group 2: 31-40 years

    The subjects will attend one single visit during which standardized photographs of the face (front and 45° left and right sides), photo shooting with a smartphone (back and front captures), LC-OCT microscopy image acquisition will be realized. The subject will have also to answer a questionnaire.

    Diagnostic Test: LC-OCT acquisitions on the forehead · Device: Perform standardized photographs using ColorFace · Device: LC-OCT acquisitions on forehead · Device: Perform photo-shooting using smartphones

  • Group 3: 41-50 years

    The subjects will attend one single visit during which standardized photographs of the face (front and 45° left and right sides), photo shooting with a smartphone (back and front captures), LC-OCT microscopy image acquisition will be realized. The subject will have also to answer a questionnaire.

    Diagnostic Test: LC-OCT acquisitions on the forehead · Device: Perform standardized photographs using ColorFace · Device: LC-OCT acquisitions on forehead · Device: Perform photo-shooting using smartphones

  • Group 4: 51-60 years

    The subjects will attend one single visit during which standardized photographs of the face (front and 45° left and right sides), photo shooting with a smartphone (back and front captures), LC-OCT microscopy image acquisition will be realized. The subject will have also to answer a questionnaire.

    Diagnostic Test: LC-OCT acquisitions on the forehead · Device: Perform standardized photographs using ColorFace · Device: LC-OCT acquisitions on forehead · Device: Perform photo-shooting using smartphones

  • Group 5: 61-75 years

    The subjects will attend one single visit during which standardized photographs of the face (front and 45° left and right sides), photo shooting with a smartphone (back and front captures), LC-OCT microscopy image acquisition will be realized. The subject will have also to answer a questionnaire.

    Diagnostic Test: LC-OCT acquisitions on the forehead · Device: Perform standardized photographs using ColorFace · Device: LC-OCT acquisitions on forehead · Device: Perform photo-shooting using smartphones

Interventions

  • Diagnostic testLC-OCT acquisitions on the forehead

    During the study visit, the investigator will for each subjects in Group 1: \- Perform standardized photographs using the ColorFace Group 2: \- Perform standardized photographs using the ColorFace Group 3: \- Perform standardized photographs using the ColorFace Group 4: * Perform standardized photographs using the ColorFace * Perform LC-OCT acquisitions on the forehead Group 5: * Perform standardized photographs using the ColorFace®; * Perform LC-OCT acquisitions on the forehead

  • DevicePerform standardized photographs using ColorFace

    Photographs

  • DeviceLC-OCT acquisitions on forehead

    Image acquisition

  • DevicePerform photo-shooting using smartphones

    photo from back and front camera pictures and selfie

06

What researchers measure

Primary outcomes

  1. Non-invasive tissue imaging: 3D imaging through Line-field Confocal Optical Coherence Tomography technology (LC-OCT) acquisitions

    Line-field Confocal Optical Coherence Tomography technology (LC-OCT) provides a unique 3D imaging modality, allowing the user to switch from a histology-like vertical mode to confocal-like horizontal mode and to record a 3D stack of tissue volumes in situ. With this technique skin can be imaged in vivo in its native state without further preparation. The superficial dermis can be clearly imaged using a live vertical, live horizontal and 3D mode. This assessment will be performed on the face (forehead) with the LC-OCT deepLive™ (DAMAE). This non invasive image will helps to characterize and quantify new metrics of skin aging linked to the dermal fibers network (collagen and elastin) such as caracterisation of the density and length of dermis fibers during aging.

    Time frame: Day 1

Secondary outcomes

  1. Standardized photographs of the face (front and 45° left and right sides)

    Standardized photographs of the face (front and 45° left and right sides) will be performed using the ColorFace (Newtone Technologies, Lyon, France). The ColorFace® has multiple lighting modes and can acquire up to 5 images in one setting from a user-definable shooting template without technician intervention. Subjects will be photographed using the following modalities: * Cross-polarized (polarizing filter angle: 90 degrees, no specular gloss on the skin surface and observation of color variations) * Standard 60 (polarizing filter angle: 60 degrees, observation of skin relief such as wrinkles) * No filter * Parallel-Polarized (polarizing filter angle: 0 degrees, observation of skin relief such as pores) * UV (observation of the pigmentation not visible to the naked eye). All the digital photographs will be identified by the protocol number, the SIN, the side photographed, the type of light used and anomyzed. They serve for illustration purposes of visible signs during skin aging .

    Time frame: Day 1

  2. Photo shooting

    Photo shooting (Back and Front camera pictures) will be performed using an iPhone 15. Back camera pictures will be taken by a trained personnel and the front camera picture will be taken by the subject himself after a brief training by the study personnel. These photos will serve for grading facial aging: Comparing the clinical assessments made by three dermatologists with those obtained by an AI-based scoring system that analyses selfie pictures.

    Time frame: Day 1

  3. Questionnaire

    Subjects will be asked to complete a self-assessment questionnaire about their lifestyle habits in order to assess the link between lifestyle habits and aging.

    Time frame: Day 1

07

Study locations

1 site
  • CPCAD, Hôpital l'Archet 2
    Nice, 06000, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Feb 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 13, 2026
StartActual
Nov 6, 2024
Primary completionActual
Feb 19, 2025
CompletionActual
Feb 19, 2025
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409675
Lead sponsor
Vichy Laboratoires
Collaborators
Centre de Pharmacologie Clinique Applique a la Dermatologie
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Nov 6, 2024
Primary completion
Feb 19, 2025
Completion
Feb 19, 2025
Last update
Feb 13, 2026

Study contacts

Catherine QUEILLE-ROUSSEL, MD
principal investigator · CPCAD, Hôpital l'Archet 2

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion